| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Dhandapani Nandakumar, Ragul Ganesh, Koushik S Deb, Raka Jain, Mamta Soo. Disability and quality of life in patients with treatment-resistant schizophrenia on long- term clozapine therapy. Indian journal of psychiatry. vol 65. issue 6. 2023-07-24. PMID:37485411. |
to assess disability and quality of life (qol) in treatment resistant schizophrenia (trs) on long term clozapine therapy and assess their correlation with positive, negative and cognitive symptoms. |
2023-07-24 |
2023-08-14 |
Not clear |
| Wen-Yin Chen, Pao-Huan Chen, Chun-Hung Pan, Sheng-Siang Su, Shang-Ying Tsai, Chiao-Chicy Chen, Chian-Jue Ku. Clozapine and its protective effect on all-cause, natural, and suicide mortality in patients with schizophrenia: A nationwide cohort study in Taiwan. Schizophrenia research. 2023-07-21. PMID:37479588. |
clozapine and its protective effect on all-cause, natural, and suicide mortality in patients with schizophrenia: a nationwide cohort study in taiwan. |
2023-07-21 |
2023-08-14 |
Not clear |
| Wen-Yin Chen, Pao-Huan Chen, Chun-Hung Pan, Sheng-Siang Su, Shang-Ying Tsai, Chiao-Chicy Chen, Chian-Jue Ku. Clozapine and its protective effect on all-cause, natural, and suicide mortality in patients with schizophrenia: A nationwide cohort study in Taiwan. Schizophrenia research. 2023-07-21. PMID:37479588. |
clozapine is indicated as the last-line agent for the treatment of refractory schizophrenia due to its side effects. |
2023-07-21 |
2023-08-14 |
Not clear |
| Wen-Yin Chen, Pao-Huan Chen, Chun-Hung Pan, Sheng-Siang Su, Shang-Ying Tsai, Chiao-Chicy Chen, Chian-Jue Ku. Clozapine and its protective effect on all-cause, natural, and suicide mortality in patients with schizophrenia: A nationwide cohort study in Taiwan. Schizophrenia research. 2023-07-21. PMID:37479588. |
this study included an asian schizophrenia population and investigated the effect of clozapine on the risks of all-cause, natural, and suicide mortality. |
2023-07-21 |
2023-08-14 |
Not clear |
| Joshep Revilla-Zúñiga, Joise Cornejo-Del Carpio, Lizardo Cruzad. Hepatoxicity induced by clozapine: Case report and brief review. Revista Colombiana de psiquiatria (English ed.). 2023-07-17. PMID:37460343. |
clozapine is an atypical antipsychotic used in treatment-resistant schizophrenia and there is evidence that it can produce elevations of hepatic transaminases, expression of liver damage in a hepatocellular pattern. |
2023-07-17 |
2023-08-14 |
Not clear |
| Drozdstoy Stoyano. Commentary: "Exploring the "Insight Paradox" in Treatment Resistant Schizophrenia: Correlations Between Dimensions of Insight and Depressive Symptoms in Patients Receiving Clozapine". Alpha psychiatry. vol 24. issue 3. 2023-07-13. PMID:37440896. |
commentary: "exploring the "insight paradox" in treatment resistant schizophrenia: correlations between dimensions of insight and depressive symptoms in patients receiving clozapine". |
2023-07-13 |
2023-08-14 |
Not clear |
| Süleyman Dönmezler, Gizem İskender, Nurhan Fıstıkcı, Yavuz Altunkaynak, Sevinç Ulusoy, Tonguç Demir Berko. Exploring the "Insight Paradox" in Treatment-Resistant Schizophrenia: Correlations Between Dimensions of Insight and Depressive Symptoms in Patients Receiving Clozapine. Alpha psychiatry. vol 24. issue 3. 2023-07-13. PMID:37440902. |
exploring the "insight paradox" in treatment-resistant schizophrenia: correlations between dimensions of insight and depressive symptoms in patients receiving clozapine. |
2023-07-13 |
2023-08-14 |
Not clear |
| Süleyman Dönmezler, Gizem İskender, Nurhan Fıstıkcı, Yavuz Altunkaynak, Sevinç Ulusoy, Tonguç Demir Berko. Exploring the "Insight Paradox" in Treatment-Resistant Schizophrenia: Correlations Between Dimensions of Insight and Depressive Symptoms in Patients Receiving Clozapine. Alpha psychiatry. vol 24. issue 3. 2023-07-13. PMID:37440902. |
we therefore set our primary aim to evaluate relationship between insight dimensions and depressive symptoms in patients with treatment-resistant schizophrenia receiving clozapine. |
2023-07-13 |
2023-08-14 |
Not clear |
| Alessandra Manca, Jacopo Mula, Alice Palermiti, Flavio Vischia, David De Cori, Sara Venturello, Guido Emanuelli, Domenico Maiese, Miriam Antonucci, Amedeo De Nicolò, Elisa Delia De Vivo, Jessica Cusato, Antonio D'Avoli. Vitamin D impact in affecting clozapine plasma exposure: A potential contribution of seasonality. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. vol 165. 2023-07-06. PMID:37413901. |
schizophrenia affects approximately 24 million people worldwide and clozapine is the most effective antipsychotic drug. |
2023-07-06 |
2023-08-14 |
Not clear |
| Shih-Ku Lin, Hsien-Yuan Lan. A brief history of clozapine use in Taiwan. Schizophrenia research. 2023-06-30. PMID:37391310. |
in conclusion, clozapine is a widely used in patients with schizophrenia in taiwan. |
2023-06-30 |
2023-08-14 |
Not clear |
| Sandeep Grover, Chandrima Naska. Patient and caregivers perspective about clozapine: A systematic review. Schizophrenia research. 2023-06-29. PMID:37385885. |
clozapine is a gold standard treatment for treatment-resistant schizophrenia. |
2023-06-29 |
2023-08-14 |
Not clear |
| Maxine Yang, Arielle Rubin, Rebecca Wondimu, Theresa Grebe, Gaby Ritfel. Significant improvement of psychotic symptoms in treatment-resistant schizophrenia with clozapine in an adolescent with SHINE syndrome: a case report. BMC psychiatry. vol 23. issue 1. 2023-06-29. PMID:37386468. |
significant improvement of psychotic symptoms in treatment-resistant schizophrenia with clozapine in an adolescent with shine syndrome: a case report. |
2023-06-29 |
2023-08-14 |
Not clear |
| Maxine Yang, Arielle Rubin, Rebecca Wondimu, Theresa Grebe, Gaby Ritfel. Significant improvement of psychotic symptoms in treatment-resistant schizophrenia with clozapine in an adolescent with SHINE syndrome: a case report. BMC psychiatry. vol 23. issue 1. 2023-06-29. PMID:37386468. |
this case illustrates the impact of clozapine in treatment-resistant early-onset psychosis and exemplifies practical implications for genetic testing in early-onset schizophrenia. |
2023-06-29 |
2023-08-14 |
Not clear |
| Guillermo Hönig, Federico M Daray, Demián Rodante, Lucas Drucaroff, María Laura Gutiérrez, Mariela Lenze, Facundo García Bournissen, Silvia Wikinsk. Body mass index, waist circumference, insulin, and leptin plasma levels differentiate between clozapine-responsive and clozapine-resistant schizophrenia. Journal of psychopharmacology (Oxford, England). 2023-06-28. PMID:37377097. |
between 25% and 50% of patients suffering from treatment-resistant schizophrenia fail to achieve a clinical response with clozapine. |
2023-06-28 |
2023-08-14 |
Not clear |
| Asmaa F Sharif, H A Aouissi, Zeinab A Kasemy, H Byeon, Heba I Lashi. Development and validation of a risk prediction nomogram for disposition of acute clozapine intoxicated patients to intensive care unit. Human & experimental toxicology. vol 42. 2023-06-28. PMID:37379491. |
clozapine is an atypical antipsychotic drug used for the treatment of refractory schizophrenia. |
2023-06-28 |
2023-08-14 |
Not clear |
| Stefan J Berger, Alex Hofe. [Safety aspects during treatment with clozapine: : Adverse effects, titration, and therapeutic drug monitoring - a narrative review]. Neuropsychiatrie : Klinik, Diagnostik, Therapie und Rehabilitation : Organ der Gesellschaft Osterreichischer Nervenarzte und Psychiater. 2023-06-22. PMID:37349671. |
according to current guidelines, clozapine should be used as a third step in treatment resistant schizophrenia (trs). |
2023-06-22 |
2023-08-14 |
Not clear |
| Jurjen J Luykx, Jairo M Gonzalez-Diaz, Ta-Wei Guu, Marte Z van der Horst, Edwin van Dellen, Marco P Boks, Sinan Guloksuz, Lynn E DeLisi, Iris E Sommer, Russel Cummins, David Shiers, Jimmy Lee, Susanna Every-Palmer, Ahmed Mhalla, Zohra Chadly, Sherry K W Chan, Robert O Cotes, Shun Takahashi, Michael E Benros, Elias Wagner, Christoph U Correll, Alkomiet Hasan, Dan Siskind, Dominique Endres, James MacCabe, Jari Tiihone. An international research agenda for clozapine-resistant schizophrenia. The lancet. Psychiatry. 2023-06-17. PMID:37329895. |
we then revisit several clozapine guidelines, the diagnostic tests and treatment options for clozapine-resistant schizophrenia, and currently applied research approaches in clozapine-resistant schizophrenia. |
2023-06-17 |
2023-08-14 |
Not clear |
| Mustafa Özdemir, Yusuf Ezel Yıldırım, Ayşegül Kar. The Impacts of Clozapine Use on the Risk and Outcomes of COVID-19 Disease in Patients with Schizophrenia. Noro psikiyatri arsivi. vol 60. issue 2. 2023-06-08. PMID:37287549. |
the impacts of clozapine use on the risk and outcomes of covid-19 disease in patients with schizophrenia. |
2023-06-08 |
2023-08-14 |
Not clear |
| Kouji Fukuyama, Eishi Motomura, Motohiro Okad. Enhanced L-β-Aminoisobutyric Acid Is Involved in the Pathophysiology of Effectiveness for Treatment-Resistant Schizophrenia and Adverse Reactions of Clozapine. Biomolecules. vol 13. issue 5. 2023-05-27. PMID:37238731. |
enhanced l-β-aminoisobutyric acid is involved in the pathophysiology of effectiveness for treatment-resistant schizophrenia and adverse reactions of clozapine. |
2023-05-27 |
2023-08-14 |
Not clear |
| Kouji Fukuyama, Eishi Motomura, Motohiro Okad. Enhanced L-β-Aminoisobutyric Acid Is Involved in the Pathophysiology of Effectiveness for Treatment-Resistant Schizophrenia and Adverse Reactions of Clozapine. Biomolecules. vol 13. issue 5. 2023-05-27. PMID:37238731. |
clozapine is an effective antipsychotic for the treatment of antipsychotic-resistant schizophrenia; however, specific types of a/b adverse effects and clozapine-discontinuation syndromes are also well known. |
2023-05-27 |
2023-08-14 |
Not clear |